NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Foamix Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.98 -0.10 (-3.25 %) (As of 12/6/2019 10:23 AM ET) Add Compare Today's Range$2.95Now: $2.98▼$3.0050-Day Range$2.73MA: $3.34▼$4.3452-Week Range$1.97Now: $2.98▼$4.48Volume135,956 shsAverage Volume691,172 shsMarket Capitalization$182.23 millionP/E RatioN/ADividend YieldN/ABeta1.53 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FOMX Previous Symbol CUSIPN/A CIK1606645 Webhttp://www.foamix.com/ Phone972-8931-6233Debt Debt-to-Equity Ratio0.24 Current Ratio5.72 Quick Ratio5.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.60 million Price / Sales50.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book1.75Profitability EPS (Most Recent Fiscal Year)($1.70) Net Income$-74,160,000.00 Net Margins-2,115.11% Return on Equity-100.58% Return on Assets-81.39%Miscellaneous Employees80 Outstanding Shares61,254,000Market Cap$182.23 million Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive FOMX News and Ratings via Email Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:FOMX Rates by TradingView Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions What is Foamix Pharmaceuticals' stock symbol? Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX." How were Foamix Pharmaceuticals' earnings last quarter? Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) posted its quarterly earnings data on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.07. Foamix Pharmaceuticals had a negative return on equity of 100.58% and a negative net margin of 2,115.11%. View Foamix Pharmaceuticals' Earnings History. When is Foamix Pharmaceuticals' next earnings date? Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Foamix Pharmaceuticals. What price target have analysts set for FOMX? 5 brokerages have issued 12-month price targets for Foamix Pharmaceuticals' stock. Their forecasts range from $10.00 to $30.00. On average, they expect Foamix Pharmaceuticals' stock price to reach $15.40 in the next twelve months. This suggests a possible upside of 417.6% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals. What is the consensus analysts' recommendation for Foamix Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals. What are Wall Street analysts saying about Foamix Pharmaceuticals stock? Here are some recent quotes from research analysts about Foamix Pharmaceuticals stock: 1. According to Zacks Investment Research, "Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. " (10/22/2019) 2. Cantor Fitzgerald analysts commented, ": Post a solid quarter of execution and ahead of two potential launches for the company, we reiterate our OW rating and 12-month PT of $15 for FOMX shares. We continue to recommend FOMX as one of our top ideas for 2019 because we think its two de-risked assets, FMX101 and FMX103, as well as additional new opportunities that leverage FOMX’s technology are all underappreciated. Therefore, upward earnings revisions should drive the stock higher. FOMX’s earnings call is 8:30AM ET tomorrow." (5/7/2019) Has Foamix Pharmaceuticals been receiving favorable news coverage? Media headlines about FOMX stock have trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Foamix Pharmaceuticals earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Foamix Pharmaceuticals. Who are some of Foamix Pharmaceuticals' key competitors? Some companies that are related to Foamix Pharmaceuticals include Canopy Rivers (RIV), Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), True Drinks (TRUU), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Beleave (BE). What other stocks do shareholders of Foamix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Foamix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Amarin (AMRN), Viking Therapeutics (VKTX), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Agile Therapeutics (AGRX), Aldeyra Therapeutics (ALDX), Galmed Pharmaceuticals (GLMD) and Rigel Pharmaceuticals (RIGL). Who are Foamix Pharmaceuticals' key executives? Foamix Pharmaceuticals' management team includes the folowing people: Mr. David T. Domzalski, CEO & Director (Age 52)Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)Dr. Iain A. Stuart, Chief R&D Officer (Age 46) Who are Foamix Pharmaceuticals' major shareholders? Foamix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (7.82%), Millennium Management LLC (0.56%), Crow Point Partners LLC (0.14%), Phoenix Holdings Ltd. (0.10%) and Stifel Financial Corp (0.03%). Company insiders that own Foamix Pharmaceuticals stock include Aharon Schwartz, Alvin D Howard, Anna Kazanchyan, David Domzalski, Iain Stuart, Ilan Hadar, Matthew T Wiley, Meir Eini, Mutya Harsch, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals. Which major investors are selling Foamix Pharmaceuticals stock? FOMX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Orbimed Advisors LLC. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include Anna Kazanchyan, David Domzalski, Iain Stuart, Ilan Hadar and Mutya Harsch. View Insider Buying and Selling for Foamix Pharmaceuticals. Which major investors are buying Foamix Pharmaceuticals stock? FOMX stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Crow Point Partners LLC and Stifel Financial Corp. Company insiders that have bought Foamix Pharmaceuticals stock in the last two years include Aharon Schwartz and Matthew T Wiley. View Insider Buying and Selling for Foamix Pharmaceuticals. How do I buy shares of Foamix Pharmaceuticals? Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Foamix Pharmaceuticals' stock price today? One share of FOMX stock can currently be purchased for approximately $2.98. How big of a company is Foamix Pharmaceuticals? Foamix Pharmaceuticals has a market capitalization of $182.23 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Foamix Pharmaceuticals employs 80 workers across the globe.View Additional Information About Foamix Pharmaceuticals. What is Foamix Pharmaceuticals' official website? The official website for Foamix Pharmaceuticals is http://www.foamix.com/. How can I contact Foamix Pharmaceuticals? Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected] MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 236 (Vote Outperform)Underperform Votes: 244 (Vote Underperform)Total Votes: 480MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: Inverted Yield Curve
